文献速递泌尿生殖技术与安全PETMRCT

早期68Ga-PSMA PET/MRI采集:同日延迟PET/CT患者中病灶可检测性与PET指标的评估

Early 68GA-PSMA PET/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET/CT.
PubMed 文献 · Clin Radiol · 2017-07-14

本研究比较了21例前列腺癌患者注射68Ga-PSMA示踪剂后立即进行的早期PET/MRI与同日PET/CT的病灶可检测性和PET指标。全身PET/MRI与PET/CT分别检出61和63个病灶,一致性极好(K=0.95),PET指标相关性很好(r=0.91),但MTV和SUVpeak的95%一致性界限远超临床可接受范围,两者指标不能互换使用。

要点

  • 全身PET/MRI与同日PET/CT病灶检出一致性极好(K=0.95,95%CI 0.89-1.0),分别检出61和63个病灶。
  • PET指标相关性很好(r=0.91,p=0.001),但MTV和SUVpeak的95%一致性界限宽,超出临床可接受范围。
  • 早期PET/MRI与PET/CT的PET指标不能互换使用。

核心结论

  • 早期PET/MRI与同日PET/CT相比,病灶可检测性一致性极好且PET指标相关性很好,但一致性界限远超临床可接受范围,因此PET/CT与早期PET/MRI的指标不能互换使用。

研究设计与样本

  • 经机构审查委员会批准、所有患者签署书面知情同意的研究,共纳入21例患者,注射68Ga-PSMA示踪剂后立即行非TOF PET/MRI两步采集(早期前列腺PET/MRI和早期全身PET/MRI),随后行全身TOF PET/CT。

诊断标准与关键数值

  • 全身PET/MRI与全身PET/CT病灶检出一致性K=0.95(95%CI 0.89-1.0)。
  • PET指标测量相关性r=0.91(p=0.001)。
  • 全身PET/CT与全身PET/MRI的MTV平均百分比差异为34.4%,95%一致性界限为-39%至107.9%。
  • 全身PET/CT与全身PET/MRI的SUVpeak平均差异为30%,95%一致性界限为-13.4%至73.4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To compare lesion detectability and positron-emission tomography (PET) metric measurements between early-PET/magnetic resonance imaging (MRI) acquisition and same-day PET/computed tomography (CT).

MATERIALS AND METHODS: The study was approved by the institutional review board and written informed consent was obtained from all patients. Twenty-one patients underwent non-time-of-flight (TOF) PET/MRI immediately following 68GA-prostate-specific membrane antigen (PSMA) tracer injection in two steps: firstly, early prostate PET/MRI (pPET/MRI) and early whole-body (WB) PET/MRI (wbPET/MR) followed by WB TOF PET/CT (wbPET/CT). Lesion detectability was compared between wbPET/MRI and wbPET/CT while PET metric measurements were compared between pPET/MR, wbPET/MRI, and wbPET/CT.

RESULTS: Sixty-one and 63 lesions were found on wbPET/MRI and wbPET/CT, respectively (K=0.95, 95% confidence interval (CI)=0.89-1.0) with very good correlation between PET metric measurements (r=0.91; p=0.001). Bland-Altman plots demonstrated a mean percentage difference between wbPET/CT with wbPET/MRI of 34.4% with 95% limits of agreement (LOA) between -39% to 107.9% for metabolic tumour volume (MTV) and a mean difference of 30% with LOA between -13.4% to 73.4% for peak standardised uptake value (SUVpeak).

CONCLUSION: Early PET/MRI demonstrates very good lesion detectability agreement and correlation with PET metrics compared to same-day PET/CT. Nevertheless, LOA are far beyond the clinically acceptable range, and therefore, PET/CT and early PET/MRI metrics cannot be used interchangeably.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Domachevsky L, Bernstine H, Goldberg N, et al. Early 68GA-PSMA PET/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET/CT. Clin Radiol. 2017. PMID: 28716214. doi:10.1016/j.crad.2017.06.116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。